繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Bio-Path Holdings Reports Tumor Regression in Early Trial for Solid Tumors; Shares Jump Pre-Bell

2024-08-21 19:59

07:59 AM EDT, 08/21/2024 (MT Newswires) -- Bio-Path Holdings (BPTH) said Wednesday that a patient treated with a higher 90 mg/m2 dose in its Phase 1/1b clinical trial of BP1001-A for solid tumors showed tumor regression and stable disease.

The company also noted "continued patient progress" in its Phase 2 triple combination study of prexigebersen in acute myeloid leukemia.

Bio-Path said supportive safety and efficacy data from both studies validate the potential of its DNAbilize platform technology to treat high-risk cancer patients.

Shares of Bio-Path were up more than 19% in Wednesday's premarket activity.

Price: 1.8190, Change: +0.33, Percent Change: +22.08

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。